Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 4 | 1 |
List of Figures | 4 | 1 |
Introduction | 5 | 1 |
Global Markets Direct Report Coverage | 5 | 1 |
Glucagon Like Peptide 2 Receptor (GLP2R) Overview | 6 | 1 |
Therapeutics Development | 7 | 3 |
Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Stage of Development | 7 | 1 |
Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Therapy Area | 8 | 1 |
Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Indication | 9 | 1 |
Glucagon Like Peptide 2 Receptor (GLP2R) Pipeline Products Glance | 10 | 2 |
Late Stage Products | 10 | 1 |
Early Stage Products | 11 | 1 |
Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Companies | 12 | 2 |
Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutics Assessment | 14 | 5 |
Assessment by Monotherapy/Combination Products | 14 | 1 |
Assessment by Mechanism of Action | 15 | 1 |
Assessment by Route of Administration | 16 | 1 |
Assessment by Molecule Type | 17 | 2 |
Glucagon Like Peptide 2 Receptor (GLP2R) Companies Involved in Therapeutics Development | 19 | 4 |
Naia Limited | 19 | 1 |
Shire Plc | 20 | 1 |
Tasly Pharmaceutical Group Co., Ltd. | 21 | 1 |
Zealand Pharma A/S | 22 | 1 |
Glucagon Like Peptide 2 Receptor (GLP2R) Drug Profiles | 23 | 12 |
FE-203799 Drug Profile | 23 | 1 |
glepaglutide Drug Profile | 24 | 2 |
GXG-8 Drug Profile | 26 | 1 |
NB-1002 Drug Profile | 27 | 1 |
teduglutide Drug Profile | 28 | 5 |
ZPGG-23 Drug Profile | 33 | 1 |
ZPGG-72 Drug Profile | 34 | 1 |
Glucagon Like Peptide 2 Receptor (GLP2R) Dormant Projects | 35 | 1 |
Glucagon Like Peptide 2 Receptor (GLP2R) Featured News &Press Releases | 36 | 13 |
Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS) | 36 | 1 |
May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome | 37 | 1 |
Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 | 38 | 1 |
Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome | 38 | 1 |
Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX | 39 | 1 |
Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan | 39 | 1 |
Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data | 40 | 1 |
Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association s (ADA) 74th Scientific Sessions | 41 | 1 |
Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome | 41 | 1 |
Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection | 42 | 1 |
Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome | 43 | 1 |
Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting | 44 | 1 |
Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome | 45 | 2 |
Jan 02, 2013: ThriveRx Receives Limited Distribution Rights To NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome In Adults | 47 | 1 |
Dec 27, 2012: Coram Specialty Infusion Services To Provide NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome | 47 | 2 |
Appendix | 49 | 2 |
Methodology | 49 | 1 |
Coverage | 49 | 1 |
Secondary Research | 49 | 1 |
Primary Research | 49 | 1 |
Expert Panel Validation | 49 | 1 |
Contact Us | 49 | 1 |
Disclaimer | 50 | 1 |